Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif Shire’s lanadelumab and SHP647 meet endpoints in respective trials http://www.drugdevelopment-technology.com/news/newsshires-lanadelumab-and-shp647-meet-endpoints-in-respective-trials-5820230 http://www.drugdevelopment-technology.com/news/newsshires-lanadelumab-and-shp647-meet-endpoints-in-respective-trials-5820230 Irish pharmaceutical company Shire has reported positive topline results from its Phase III HELP clinical trial of lanadelumab to treat hereditary angioedema (HAE) and from the Phase II TURANDOT trial of SHP647 (PF-00547659) for the treatment of ulce… Sun, 21 May 2017 23:00:00 GMT Albireo to initiate A4250’s Phase III clinical programme to treat PFIC http://www.drugdevelopment-technology.com/news/newsalbireo-to-initiate-a4250s-phase-iii-clinical-programme-to-treat-pfic-5820238 http://www.drugdevelopment-technology.com/news/newsalbireo-to-initiate-a4250s-phase-iii-clinical-programme-to-treat-pfic-5820238 Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). Sun, 21 May 2017 23:00:00 GMT Majority of UC Cases Considered Mild to Moderate http://www.drugdevelopment-technology.com/news/newsmajority-of-uc-cases-considered-mild-to-moderate-5820406 http://www.drugdevelopment-technology.com/news/newsmajority-of-uc-cases-considered-mild-to-moderate-5820406 Publication Date: Month 2017 Ulcerative colitis (UC) can be a significant cause of morbidity and worsen the quality of life for individuals with the disease, especially in its most severe form. In UC, the symptoms vary depending on the severity and c… Sun, 21 May 2017 23:00:00 GMT Myovant reports positive data from Phase II trial of relugolix in Japan for endometriosis http://www.drugdevelopment-technology.com/news/newsmyovant-reports-positive-data-from-phase-ii-trial-of-relugolix-in-japan-for-endometriosis-5820361 http://www.drugdevelopment-technology.com/news/newsmyovant-reports-positive-data-from-phase-ii-trial-of-relugolix-in-japan-for-endometriosis-5820361 Myovant Sciences has reported positive results from the Phase II clinical trial of relugolix in Japan to treat pain associated with endometriosis in women. Sun, 21 May 2017 23:00:00 GMT Deals this week: Genoa Pharmaceuticals, Dragonfly Therapeutics, Biomx http://www.drugdevelopment-technology.com/news/newsdeals-this-week-genoa-pharmaceuticals-inc-dragonfly-therapeutics-inc-biomx-ltd-5817270 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-genoa-pharmaceuticals-inc-dragonfly-therapeutics-inc-biomx-ltd-5817270 US-based pharmaceutical company Genoa Pharmaceuticals has completed a series A venture financing round led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners and participated by three other investors. Thu, 18 May 2017 23:00:00 GMT Aurinia begins voclosporin dosing in Phase III trial for LN http://www.drugdevelopment-technology.com/news/newsaurinia-begins-voclosporin-dosing-in-phase-iii-trial-for-ln-5818511 http://www.drugdevelopment-technology.com/news/newsaurinia-begins-voclosporin-dosing-in-phase-iii-trial-for-ln-5818511 Canadian-based biopharmaceutical firm Aurinia Pharmaceuticals has begun dosing patients in the Phase III AURORA clinical trial of voclosporin to treat lupus nephritis (LN). Thu, 18 May 2017 23:00:00 GMT Dinutuximab beta for the Treatment of Neuroblastoma http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. Thu, 18 May 2017 23:00:00 GMT Medical research funders and NGOs agree on new WHO clinical trial policies http://www.drugdevelopment-technology.com/news/newsmedical-research-funders-and-ngos-agree-on-new-who-clinical-trial-policies-5818523 http://www.drugdevelopment-technology.com/news/newsmedical-research-funders-and-ngos-agree-on-new-who-clinical-trial-policies-5818523 The majority of medical research funders and international non-governmental organisations (NGOs) have agreed to implement the new World Health Organisation (WHO) standards for clinical trials. Thu, 18 May 2017 23:00:00 GMT M&As this week: Thermo Fisher Scientific, Norgine http://www.drugdevelopment-technology.com/news/newsmas-this-week-thermo-fisher-scientific-inc-norgine-5817273 http://www.drugdevelopment-technology.com/news/newsmas-this-week-thermo-fisher-scientific-inc-norgine-5817273 US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash. Thu, 18 May 2017 23:00:00 GMT Syndax’s entinostat advances into second stage of Phase II trial for NSCLC http://www.drugdevelopment-technology.com/news/newssyndaxs-entinostat-advances-into-second-stage-of-phase-ii-trial-for-nsclc-5817223 http://www.drugdevelopment-technology.com/news/newssyndaxs-entinostat-advances-into-second-stage-of-phase-ii-trial-for-nsclc-5817223 US-based biopharmaceutical firm Syndax Pharmaceuticals’ entinostat has advanced into the second stage of Phase II of the ENCORE 601 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC). Wed, 17 May 2017 23:00:00 GMT Interface Clinical Research develops new GP model to minimise clinical trial drop outs http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-develops-new-gp-model-to-minimise-clinical-trial-drop-outs-5817230 http://www.drugdevelopment-technology.com/news/newsinterface-clinical-research-develops-new-gp-model-to-minimise-clinical-trial-drop-outs-5817230 Interface Clinical Services’ division Interface Clinical Research has developed a new model to decrease the number of patient dropouts from clinical trials. Wed, 17 May 2017 23:00:00 GMT Capecitabine improves post-surgery survival period in bile duct cancer patients http://www.drugdevelopment-technology.com/news/newscapecitabine-improves-post-surgery-survival-period-in-bile-duct-cancer-patients-5817763 http://www.drugdevelopment-technology.com/news/newscapecitabine-improves-post-surgery-survival-period-in-bile-duct-cancer-patients-5817763 A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. Wed, 17 May 2017 23:00:00 GMT Actinogen begins enrolment in Phase II trial of Xanamem to treat Alzheimer’s disease http://www.drugdevelopment-technology.com/news/newsactinogen-begins-enrolment-in-phase-ii-trial-of-xanamem-to-treat-alzheimers-disease-5815838 http://www.drugdevelopment-technology.com/news/newsactinogen-begins-enrolment-in-phase-ii-trial-of-xanamem-to-treat-alzheimers-disease-5815838 Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer's disease. Tue, 16 May 2017 23:00:00 GMT Immunovaccine to study DPX-Survivac in Phase II combination trial for DLBCL http://www.drugdevelopment-technology.com/news/newsimmunovaccine-to-study-dpx-survivac-in-a-phase-ii-combination-trial-for-dlbcl-5816546 http://www.drugdevelopment-technology.com/news/newsimmunovaccine-to-study-dpx-survivac-in-a-phase-ii-combination-trial-for-dlbcl-5816546 Canadian-based immuno-oncology company Immunovaccine is set to evaluate its DPX-Survivac in combination with a PD-1 checkpoint inhibitor and a low-dose cyclophosphamide in its Phase II clinical trial to treat measurable or recurrent diffuse large B-C… Tue, 16 May 2017 23:00:00 GMT Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours http://www.drugdevelopment-technology.com/news/newssyros-starts-dosing-in-phase-i-trial-of-sy-1365-to-treat-solid-tumours-5815827 http://www.drugdevelopment-technology.com/news/newssyros-starts-dosing-in-phase-i-trial-of-sy-1365-to-treat-solid-tumours-5815827 US-based biopharmaceutical company Syros Pharmaceuticals has started dosing patients in its Phase I clinical trial of SY-1365 for the treatment of patients with advanced solid tumours. Tue, 16 May 2017 23:00:00 GMT Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Tue, 16 May 2017 23:00:00 GMT Analysing Polysaccharides Using OMNISEC http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/analysing-polysaccharides-using-omnisec/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/analysing-polysaccharides-using-omnisec/ Malvern notes how moving to multi-detector gel permeation chromatography (GPC) or size-exclusion chromatography (SEC) can provide greater insight than conventional measurements. Tue, 16 May 2017 14:59:00 GMT Malvern Instruments -Biopharmaceutical and Drug Development http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/ http://www.drugdevelopment-technology.com/contractors/delivery/malvern-drug-development/ Malvern offers characterisation tools for molecular analysis and small drug discovery to help accelerate development for the pharmaceutical industry. Tue, 16 May 2017 14:58:00 GMT AstraZeneca’s Imfinzi meets primary endpoint in Phase III trial for stage III NSCLC http://www.drugdevelopment-technology.com/news/newsastrazenecas-imfinzi-meets-primary-endpoint-in-phase-iii-trial-for-stage-iii-nsclc-5814590 http://www.drugdevelopment-technology.com/news/newsastrazenecas-imfinzi-meets-primary-endpoint-in-phase-iii-trial-for-stage-iii-nsclc-5814590 AstraZeneca and its biologics research and development arm MedImmune have reported positive results from the Phase III PACIFIC clinical trial of Imfinzi (durvalumab) to treat patients with locally advanced, unresectable (stage III) non-small-cell lun… Mon, 15 May 2017 23:00:00 GMT Glenmark Pharmaceuticals to investigate GBR 1342 in Phase I trial for multiple myeloma http://www.drugdevelopment-technology.com/news/newsglenmark-pharma-to-investigate-gbr-1342-in-phase-i-trial-for-multiple-myeloma-5815187 http://www.drugdevelopment-technology.com/news/newsglenmark-pharma-to-investigate-gbr-1342-in-phase-i-trial-for-multiple-myeloma-5815187 Indian pharmaceutical firm Glenmark Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase I clinical trial of GBR 1342 to treat patients with multi… Mon, 15 May 2017 23:00:00 GMT